RWM
AMPH icon

Rialto Wealth Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Rialto Wealth Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23
Closed -$613 – 1698
2025
Q3 		$613 Buy
23
+3
+15% +$77 ﹤0.01% 1119
2025
Q2 		$460 Buy
+20
New +$496 ﹤0.01% 1200

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rialto Wealth Management's AMPH Position: Q4 2025 in Review

Rialto Wealth Management sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2025, closing a stake of 23 shares — an estimated $613 sold.

Rialto Wealth Management first reported a position in AMPH in Q2 2025 and held it in 2 quarters. The position peaked at $613 in Q3 2025. 235 funds tracked by Wall St. Rank hold AMPH as of Q4 2025.

  • Rialto Wealth Management reported no remaining Amphastar Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Rialto Wealth Management sold 23 Amphastar Pharmaceuticals shares in Q4 2025, an estimated $613.
  • Rialto Wealth Management first reported a position in Amphastar Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Rialto Wealth Management's Amphastar Pharmaceuticals position peaked at $613 in Q3 2025.
  • 235 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2025.

Based on Rialto Wealth Management's 13F filing for Q4 2025, filed 12 Jan 2026.